STOCK TITAN

Tempus AI - TEM STOCK NEWS

Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.

Tempus AI Inc (NASDAQ: TEM) pioneers AI-driven healthcare solutions through its proprietary data integration platform. This news hub provides investors and healthcare professionals with essential updates on the company's technological advancements, strategic partnerships, and financial developments.

Access real-time announcements covering TEM's innovations in diagnostic analytics, generative AI applications, and healthcare data ecosystem expansions. Our curated collection includes earnings reports, regulatory filings, and analyses of platform enhancements that power precision medicine.

Key focus areas include AI-powered laboratory solutions, clinical research collaborations, and progress in breaking healthcare data silos. Stay informed about TEM's role in advancing personalized diagnostics through machine learning and large language model implementations.

Bookmark this page for verified updates on TEM's operational milestones, directly sourced from official communications. Monitor how the company continues redefining medical data utilization while maintaining HIPAA-compliant security standards across its platform.

Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has unveiled new generative AI capabilities for its Tempus One platform, enhancing its ability to analyze unstructured healthcare data. The platform now features four key innovations: Patient Query for improved clinical trial matching, Patient Timeline for comprehensive patient journey visualization, Prior Authorization to streamline administrative processes, and Data Exploration for advanced research capabilities.

These new features leverage Tempus' proprietary Large Language Model (LLM) Agent Infrastructure to process millions of unstructured documents, including progress notes, pathology reports, and imaging scans. The system can now create structured timelines of clinical events, facilitate patient enrollment in clinical trials, assist with prior authorization documentation, and enable researchers to analyze de-identified datasets more efficiently.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) announced the development of xH, its first whole-genome sequencing (WGS) test, focusing on hematological oncology. The test, currently available for research use only, will be clinically available within the next year. xH is designed to support both clinicians and biopharma collaborators by providing comprehensive genetic profiling.

In a pilot study of 135 patients, the WGS assay demonstrated high accuracy with a concordance rate exceeding 98.9% compared to traditional molecular methods. The test showed particular effectiveness in detecting guideline-recommended structural variants and large copy number alterations in myeloid malignancies, including Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Myeloproliferative neoplasms. This comprehensive approach aims to consolidate multiple tests into a single assay, potentially offering a more cost-effective solution for genomic profiling.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.81%
Tags
none
-
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) released preliminary, unaudited results for Q4 and full year 2024. The company reported approximate full-year revenue of $693 million, showing ~30% year-over-year growth, and Q4 revenue of $200 million, representing ~35% year-over-year growth.

The company's genomics revenue is expected to grow ~30% in Q4, while data and services revenue is projected to grow ~45%. Tempus expects to achieve ~99% of its 2024 revenue guidance and ~100% of adjusted EBITDA guidance, despite noting some softness in CRO revenues. Both Q4 and full-year results showed continued improvement in adjusted EBITDA compared to previous periods.

These preliminary results are subject to change pending completion of year-end close and review procedures. Final detailed financial results will be reported during the company's first earnings call of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.81%
Tags
Rhea-AI Summary

Tempus (NASDAQ: TEM) announced a multi-year collaboration with Genialis to develop RNA-based biomarker algorithms for cancer treatment. Genialis will utilize Tempus' multimodal dataset to validate and enhance their AI foundation model, which uses data from approximately 1 million RNA-sequencing samples.

Through this partnership, Genialis gains access to Tempus' analytics platform, Lens, providing development tools and de-identified patient records. In return, Tempus receives rights to evaluate and potentially license Genialis-developed algorithms for commercialization within their xR platform.

The collaboration has already contributed to the launch of Genialis™krasID, the first commercial algorithm predicting patient response to KRAS-targeted therapies across cancer types. This algorithm, validated using Tempus' real-world data, effectively stratifies patients into response likelihood groups.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
none
-
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's involvement includes two key events:

1. A presentation and Q&A session with investors led by Founder and CEO Eric Lefkofsky on Monday, January 13

2. A panel discussion on Policy Outlook for Artificial Intelligence in Healthcare & Diagnostics featuring Chief Scientific Officer Kate Sasser on Wednesday, January 15

The company will provide a live webcast option for accessing the January 13 presentation. Tempus AI specializes in leveraging artificial intelligence to enhance precision medicine and improve patient care outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
conferences
-
Rhea-AI Summary

Tempus has secured in-network provider status with several major healthcare insurers, including Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions. Through the Avalon agreement, Tempus becomes a participating provider with BCBS entities in North Carolina, South Carolina, Vermont, as well as Capital BlueCross and CareSource in four markets. This expansion enhances Tempus' presence with commercial health plans in the East.

The agreements enable patients with these insurance plans to access Tempus' comprehensive molecular profiling portfolio as a participating provider, potentially leading to lower out-of-pocket costs for testing services. These molecular profiling tests help physicians make more informed, personalized treatment decisions throughout patients' care journeys.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.95%
Tags
none
Rhea-AI Summary

Tempus AI (NASDAQ: TEM) announces a significant Medicare coverage decision for its ECG-AF device. The Centers for Medicare and Medicaid Services (CMS) will provide reimbursement for cardiac dysfunction assessments using the Tempus ECG-AF algorithm, with a Medicare rate of $128.90 effective January 1, 2025.

The FDA-cleared device analyzes 12-lead ECG recordings to detect signs of atrial fibrillation (AF) risk within 12 months for patients 65 and older. This development follows Tempus' earlier FDA 510(k) clearance, marking the first AF indication in cardiovascular machine learning-based notification software. With nearly one million Americans having undetected AF and over 100 million ECGs performed annually in the U.S., this AI-powered solution aims to enhance early disease detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Summary

Personalis (Nasdaq: PSNL) and Tempus AI (Nasdaq: TEM) have expanded their commercial relationship to benefit the biopharma industry. Originally agreed upon in November 2023, the collaboration aims to bring ultra-sensitive MRD testing to market. The partnership was launched at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, with Tempus serving as the exclusive commercial diagnostic partner for Personalis' NeXT Personal® Dx. This product is designed for broad patient adoption in breast and lung cancers and immunotherapy monitoring across all solid tumors.

Following a positive market reaction, Tempus will now offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers. These customers can bundle MRD testing with other Tempus offerings within a given study. Chris Hall, CEO of Personalis, believes that this expansion will accelerate market penetration and capitalize on new opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
-
Rhea-AI Summary

Healthcare executives are increasingly adopting generative AI, with 90% reporting positive ROI from their investments. The Global AI in Healthcare Market is projected to reach $164.16 billion by 2030, growing at a 49.1% CAGR. In a significant development, Avant Technologies has partnered with Roche and Salud 360 to launch a pilot program in Costa Rica targeting diabetic retinopathy using AI technology. The program utilizes non-mydriatic fundus cameras and AI to analyze retinal images for early detection of the condition. Initially implemented in Costa Rica, where diabetes affects 10.4% of adults, the program aims to expand to the US, Canada, and Europe if successful.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
AI
Rhea-AI Summary

Tempus AI (NASDAQ: TEM), a leader in AI-driven precision medicine and healthcare technology, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place in New York on December 3, 2024. Tempus Founder and CEO Eric Lefkofsky is scheduled to engage in a fireside discussion at 3:00 p.m. ET during the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
conferences
Tempus AI

Nasdaq:TEM

TEM Rankings

TEM Stock Data

7.00B
93.14M
47.69%
34.24%
8.23%
Health Information Services
Services-computer Programming, Data Processing, Etc.
Link
United States
CHICAGO